Abstracts tagged "Rheumatoid Factor"

Abstract Number: 0273 • ACR Convergence 2021
Abnormalities in Left Ventricular Geometry Influenced by Higher Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Titers in Rheumatoid Arthritis Patients
Natalia Guajardo-Jauregui, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Alejandra Rodriguez-Romero, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Catalina Andrade-Vazquez and Alan De Leon-Yañez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher risk of developing left ventricular (LV) geometry abnormalities which can result in cardiac death. High titers of…
Abstract Number: 0440 • ACR Convergence 2021
Association Between Rheumatic Autoantibody Positivity and Immune-related Adverse Events
Kristen Mathias¹, Marco Lopez Velazquez¹ and Pankti Reid², ¹University of Chicago, Chicago, IL, ²University of Chicago Medical Center, Chicago, IL
Background/Purpose: The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy; however, their use can lead to off-target toxicities called immune-related adverse events (irAEs)…
Abstract Number: 0463 • ACR Convergence 2021
Treatment Persistence Among Medicare Beneficiaries with Seropositive Rheumatoid Arthritis Initiating Biologic or Targeted Synthetic DMARDs
Sang Hee Park¹, Taylor Schwartz², Xue Han¹, Scott Robinson², Sumie Kakehi¹, Keith Wittstock¹, Kris Norris², Anne Murunga², Alison Silverstein² and Jeffrey Sparks³, ¹Bristol Myers Squibb, Princeton, NJ, ²Avalere Health, Washington, DC, ³Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Recent exploratory clinical trial and retrospective studies1 suggest that patients with seropositive RA (rheumatoid factor [RF]+ and/or anti-cyclic citrullinated peptide [anti-CCP]+) treated with abatacept…
Abstract Number: 0568 • ACR Convergence 2021
Construction of the Veterans Affairs National Rheumatoid Arthritis Database (VANRAD)
Amy Joseph¹, Jodi Yanagida¹, Xinliang Huang¹, Prabha Ranganathan¹, Melissa Laurie², Hong Xian¹ and Seth Eisen¹, ¹VA St. Louis Health Care System, St. Louis, MO, ²Bristol Myers Squibb, Princeton, NJ
Background/Purpose: The Department of Veterans Affairs (DVA) provides comprehensive medical care at minimal or no cost to 9 million veterans annually through 170 medical centers…
Abstract Number: 1230 • ACR Convergence 2021
Impact of Serologic Status on Clinical Responses to Upadacitinib or Abatacept in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Biologic DMARDs: Sub-Group Analysis from the Phase 3 SELECT-CHOICE Study
Andrea Rubbert-Roth¹, Jeffrey Sparks², Arnaud Constantin³, Ricardo Xavier⁴, Yanna Song⁵, Jessica Suboticki⁵ and Roy Fleischmann⁶, ¹Kantonspital St Gallen, St.Gallen, Switzerland, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Toulouse University Hospital, Toulouse Cedex 9, France, ⁴Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁵AbbVie Inc., North Chicago, IL, ⁶University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In patients with RA who had a prior inadequate response or intolerance to biologic DMARDs, the oral Janus kinase inhibitor, upadacitinib (UPA), demonstrated superiority…
Abstract Number: 1517 • ACR Convergence 2021
Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade
Sophia Weinmann¹, Amanda Eudy² and David Pisetsky¹, ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: Patients with malignancy who develop rheumatic immune related adverse events (IRAEs) during immune checkpoint blockade (ICB) are commonly autoantibody negative. The change from chemotherapy…
Abstract Number: 1648 • ACR Convergence 2021
Increasing Rates of Positivity of Autoantibodies Indicates a Shorter Time-to-Diagnosis of Future Rheumatoid Arthritis
Dylan Bergstedt¹, Ryan Peterson², Marie Feser¹, LauraKay Moss¹, Geoffrey Thiele³, Ted Mikuls³, Jess Edison⁴, V. Michael Holers¹ and Kevin Deane⁵, ¹University of Colorado Denver, Aurora, CO, ²Colorado School of Public Health, Aurora, CO, ³University of Nebraska Medical Center, Omaha, NE, ⁴Walter Reed National Military Medical Center, Bethesda, MD, ⁵University of Colorado Denver, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations in autoantibodies to citrullinated protein antigens (ACPA) and rheumatoid factor (RF)…
Abstract Number: 1698 • ACR Convergence 2020
Polyarthritis Workup in Primary Care Setting : How Are We Doing?
Ruhani Desai¹, Cassandra Calabrese², Neel Patel³ and Jessica Donato⁴, ¹Cleveland Clinic Foundation, DeLand, FL, ²Cleveland Clinic, Cleveland, OH, ³Case Western Reserve University, Cleveland, OH, ⁴Cleveland Clinic Foundation, Cleveland
Background/Purpose: Joint pain is a common presenting complaint in Primary Care with around 54.4 million adults diagnosed with some form of arthritis per 2013 CDC survey. Polyarthritis…
Abstract Number: 1720 • ACR Convergence 2020
Factors Associated with an Increased Risk of Imminent Rheumatoid Arthritis in ACPA+ Individuals
Hyoun-Ah Kim¹, Ryan Peterson², Gary Firestein³, David Boyle⁴, Jane Buckner⁵, Sylvia Posso⁶, Eddie James⁵, William Robinson⁷, Jaron Arbet², LauraKay Moss⁸, Roger Gilmore⁸, Lindsay Hartje⁸, Saman Barzideh⁸, Jennifer Seifert⁹, Navin Rao¹⁰, Frédéric Baribaud¹¹, Sunil Nagpal¹², Alyssa Johnson¹³, V Michael Holers¹⁴ and Kevin D. Deane¹⁵, ¹University of Colorado Anschutz Medical Campus and Ajou University School of Medicine, Aurora, CO, ²Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, ³University of California, San Diego, La Jolla, CA, ⁴UC San Diego, San Diego, CA, ⁵Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Stanford University, Palo Alto, CA, ⁸University of Colorado Anschutz Medical Campus, Aurora, CO, ⁹Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Littleton, CO, ¹⁰Janssen R&D, Spring House, PA, ¹¹Janssen Research & Development, LLC, Spring House, PA, ¹²Janssen Reserach and Development, Spring House, PA, ¹³Janssen Research and Development, Spring House, PA, ¹⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ¹⁵2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado
Background/Purpose: Individuals at high-risk for future rheumatoid arthritis (RA) may be identified by screening for circulating RA-related autoantibodies including antibodies to citrullinated protein antigens (ACPA).…
Abstract Number: 1721 • ACR Convergence 2020
Increasing Autoantibody Positivity During Pre-RA Is Associated with the Imminent Development of Classifiable RA
Heinrich-Karl Greenblatt¹, Ted Mikuls², Jess Edison³, Marie Feser⁴, Mark Parish⁵, LauraKay Moss⁵, Elizabeth Mewshaw⁶ and Kevin D. Deane⁷, ¹University of Colorado School of Medicine, Aurora, CO, ²University of Nebraska Medical Center, Omaha, NE, ³Walter Reed National Military Medical Center, Bethesda, ⁴Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Walter Reed National Military Medical Center, Bethesda, MD, ⁷2 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado
Background/Purpose: Autoantibodies including rheumatoid factor (RF) and antibodies to citrullinated protein antigens (ACPA) may be elevated during a period that can be termed ‘Pre-RA’. In…
Abstract Number: 1753 • ACR Convergence 2020
Substantial Work Limitations in Patients with Rheumatoid Arthritis Despite Optimal Treat-to-Target (T2T) Drug Therapy Intervention
Sara Eileen Meyer¹, Julianna Rachel Hoeper², Kirsten Hoeper¹, Torsten Witte³ and Dirk Meyer-Olson⁴, ¹Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., Hanover, Germany, ²Center for Health Economics Research Hannover, Leibniz Universität Hannover, Hannover, Hanover, Germany, ³Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., Hannover, Germany, ⁴Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., m&i Fachklinik Bad Pyrmont und Medizinisches Forschungszentrum Weserbergland, Hanover, Germany
Background/Purpose: Rheumatoid arthritis (RA) is associated with restrictions on occupational participation caused by periods of sick leave (absenteeism), reduced productivity at work due to disease…
Abstract Number: 0157 • ACR Convergence 2020
Early Arthritis Global Assesment: What Differences Exist Between Patients and Physicians?
Cristina Valero¹, Noelia Garcia¹, Juan Pablo Baldivieso², Ana Ortiz³, Sebastian Rodriguez² and Isidoro González-Álvaro³, ¹Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ²Hospital de La Princesa, Madrid, Madrid, Spain, ³Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Madrid, Spain
Background/Purpose: In recent years there is increasing evidence of the relevance of including the assessment of the different aspects of rheumatoid arthritis (RA) from the…
Abstract Number: 0182 • ACR Convergence 2020
Chronic Kidney Disease Is Underestimated in Patients with Rheumatoid Arthritis – Real World Data Gathered from a Network of Rheumatologists
Stefan Kleinert¹, Peter Bartz-Bazzanella², Cay von der Decken³, Kirsten Karberg⁴, Florian Schuch⁵, Georg Gauler⁶, Patrick Wurth⁷, Susanna Spaethling-Mestekemper⁸, Christoph Kuhn⁹, Matthias Englbrecht¹⁰, Wolfgang Vorbrueggen¹¹ and Martin Welcker¹², ¹Rheumatology-Nephrology Practice, Erlangen, Germany, ²Department of Rheumatology, Internal Medicine, Rhein-Maas-Hospital, Wuerselen, Germany, ³Medical Centre Stolberg, Stolberg, Germany, ⁴Practice for Rheumatology and Internal Medicine, Berlin, Germany, ⁵Rheumatology-Nephrology Practice, Erlangen, ⁶Rheumatology Practice, Osnabrueck, ⁷Rheumatology Practice, Osnabrueck, Germany, ⁸Rheumatology Group Practice, Muenchen, Germany, ⁹Rheumatology Practice, Karlsruhe, ¹⁰Freelance Healthcare Data Scientist, Eckental, Germany, ¹¹Foundation for fostering rheumatology, Wuerselen, Germany, ¹²MVZ für Rheumatologie Dr. M. Welcker, Planegg, Germany
Background/Purpose: Patient registries have become a common approach to learn from patient-related data by prospectively including large numbers of individuals into a sample followed over…
Abstract Number: 0754 • ACR Convergence 2020
The Association Between Continuous Decreases in Serum RF Titers and Radiographic Remission of Joint Damage in RA Patients Treated with Biological or Targeted Synthetic DMARDs
Takayoshi Owada¹, Ayae Tanaka², Hirokuni Hirata¹, Masafumi Arima³, Yasutsugu Fukushima¹ and Kazuhiro Kurasawa³, ¹Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan, ²Dokkyo Medical University, Shimotsuga-Gun, Japan, ³Dokkyo Medical University, Mibu, Shimotsugagun, Tochigi, Japan
Background/Purpose: Rheumatoid factors (RFs) are RA-related autoantibodies like anti-cyclic citrullinated peptide antibodies, and are used for classifying and diagnosing RA. In addition, positivity and high…
Abstract Number: 0758 • ACR Convergence 2020
Anti-citrullinated Protein Antibodies Are Associated with Functional Disability in Unaffected First-degree Relatives of Rheumatoid Arthritis Patients
Dana Wiens¹, Irene Smolik¹, Xiaobo Meng¹, Vidyanand Anaparti¹, Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: The preclinical stage of Rheumatoid Arthritis (RA) is characterized by seropositivity for anti-citrullinated protein antibodies (ACPA). We (PubMed ID 30861615), and others, have shown that ACPA seropositivity…

« Previous Page
1
…
4
5
6
7
8
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].